VBVijay Bhoopalan

Vijay Bhoopalan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vijay Bhoopalan has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia

    by Nadine Hein, Perlita Poh, Jason A. Powell, Lorena Núñez Villacís, Sarah Sant’ANna Maranhão, Maurits Evers, Jirawas Sornkom, Victoria S. Pope, Priscilla Soo, Adria Closa, et al.

    Despite advances in therapy, specific subtypes of Acute Myeloid Leukemia (AML) remain largely incurable. The small molecule drug CX-5461 exhibits dual target specificity, acting as a first-in-class ribosome biogenesis inhibitor to induce the nucleolar surveillance pathway (NSP), as well as to poison Topoisomerase IIα (TOPIIA) to induce DNA damage. We conducted a phenotypic screen of FDA-approved drugs to identify compounds that synergies with CX-5461 to enhance the therapeutic efficacy of this drug in incurable AML. The pan-CDK inhibitors Dinaciclib and Flavopiridol were identified as efficient combinatorial therapies with CX-5461. Dinaciclib acts synergistically across a genetically divergent panel of human AML cell lines, significantly improves survival in murine AML models, and reduces colony formation in primary human AML samples. Synergy was attributable, at least partially, to combinatorial activation of the NSP. Both agents independently stabilized p53 but produced distinct biological outcome; Dinaciclib driving rapid apoptosis and CX-5461 primarily promoting cell-cycle arrest; which together yielded efficient tumor clearance and delayed onset of therapy resistance. These findings provide strong evidence that a combination treatment strategy that leverages nucleolar stress and cell cycle control to enhance treatment outcomes in AML, paving the way for clinical translation of Pol I-CDK co-targeting therapies.

  • Open Access

    Platelet triggering receptor expressed on myeloid cells–like transcript 1 regulation in healthy donors and patients at risk of bleeding and thrombosis

    by Amandeep Kaur, Sidra A. Ali, Marcus Alim, Ziliang R. Chen, Vijay Bhoopalan, Samantha J. Montague, Yee Lin Thong, Mikhail Danilov, Justin J. Xia, Jordan Ross, et al.

  • Open Access

    Platelet dysfunction in immune thrombocytopenia: Finding clinical subsets with platelet phenotypes

    by Sidra A. Ali, Sarah M. Hicks, Lucy A. Coupland, Simone A. Brysland, Vijay Bhoopalan, Yee Lin Thong, Amandeep Kaur, Robert K. Andrews, Elizabeth E. Gardiner, Philip Y.‐I. Choi

    Summary: Patients with immune thrombocytopenia (ITP) remain a challenge to diagnose, manage and predict bleeding risk. A comprehensive assessment of platelet function may aid clinical management. This study assessed platelet parameters to predict bleeding in ITP. Blood from 103 clinically annotated cases with isolated thrombocytopenia and 123 healthy donors was evaluated. In the ITP cohort, 75/110 encounters (68%) had platelet counts below 50 × 10 9 /L. Platelet surface proteins, reticulated platelets and activation were quantified using flow cytometry. Soluble receptor fragments, citrullinated histone‐DNA (CitH3‐DNA) complexes and thrombopoietin (TPO) were quantified by enzyme‐linked immunosorbent assay (ELISA). Whole blood clotting and platelet contribution to clot formation were evaluated using viscoelastography. Elevated levels of glycoprotein (GP) VI ( p = 0.0012), Trem‐like transcript‐1 (TLT‐1) ( p = 0.0248), platelet‐bound immunoglobulin (Ig) G ( p < 0.0029), CitH3‐DNA complexes ( p = 0.0022), TPO ( p < 0.0001) and reduced platelet contribution to clot formation ( p < 0.0001) were observed in primary ITP patients with bleeding and bruising symptoms. A multivariable analysis revealed that measuring platelet indices strengthened a predictive bleeding model over platelet count alone (78.1% vs. 70.48%). Symptomatic ITP patients have measurable platelet dysfunction and quantifiable differences on platelet surface, increased evidence of NETosis and elevated TPO levels. Identifying biomarkers for ITP outcomes can define subsets of disease with clinical relevance.


  • Open Access

    Treatment with the ribosome biogenesis inhibitor CX-5461 increases platelet count in humans and enhances murine megakaryopoiesis

    by Vijay Bhoopalan, Amandeep Kaur, James I. Hearn, Kylee H. Maclachlan, Lixinyu Liu, Rita Ferreira, Sidra A. Ali, Yee Lin Thong, Nadine Hein, Samina Nazir, et al.

    Thrombocytopenia is a common and serious complication of anticancer therapies. Here, we identify a novel thrombopoietic activity of the first-in-class ribosome biogenesis inhibitor CX-5461. In a phase I trial, 56% (9/16) of patients exhibited up to a 34% increase in platelet count following a single dose of CX-5461. In mice, CX-5461 elicited a rapid, reversible, and sustained ∼1.7-fold increase in platelet numbers without altering platelet function, lifespan, or inflammatory cytokines. Bone marrow analysis revealed a specific expansion of megakaryocytes (MKs), increased Sca1⁺ MKs, and selective enrichment of MK-biased multipotent progenitor 2, independent of thrombopoietin (TPO) or c-mpl signalling. CX-5461 also mitigated carboplatin-induced thrombocytopenia, accelerating platelet recovery. Single-cell RNA sequencing and RNA velocity analysis confirmed enhanced differentiation of MK progenitors. These findings demonstrate that inhibition of ribosome biogenesis promotes TPO-independent megakaryopoiesis and identifies a previously unrecognised therapeutic opportunity to support platelet recovery in cancer treatment and potentially other thrombocytopenic states.

  • Open Access

    Patients with Waldenström macroglobulinemia have impaired platelet and coagulation function

    by Simone A. Brysland, Dipti Talaulikar, Sarah M. Hicks, James I. Hearn, Sidra A. Ali, Muhammad Gohar Maqbool, Mridula Mokoonlall, Vijay Bhoopalan, Amandeep Kaur, Yee Lin Thong, et al.

    Clinical features in patients with the B-cell lymphoma, Waldenström macroglobulinemia (WM), include cytopenias, immunoglobulin M (IgM)–mediated hyperviscosity, fatigue, bleeding, and bruising. Therapeutics such as Bruton's tyrosine kinase inhibitors (BTKis) exacerbate bleeding risk. Abnormal hemostasis arising from platelet dysfunction, altered coagulation or vascular impairment have not yet been investigated in patients with WM. Therefore, this study aimed to evaluate hemostatic dysfunction in samples from these patients. Whole blood (WB) samples were collected from 14 patients with WM not receiving therapy, 5 patients receiving BTKis and 15 healthy donors (HDs). Platelet receptor levels and reticulation were measured by flow cytometry, plasma thrombin generation with or without platelets by fluorescence resonance energy transfer assay, WB clotting potential by rotational thromboelastometry, and plasma soluble glycoprotein VI (sGPVI) and serum thrombopoietin (TPO) by enzyme-linked immunosorbent assay. Donor platelet spreading, aggregation, and ability to accelerate thrombin generation in the presence of WM-derived IgM were assessed. WM platelet receptor levels, responses to physiological agonists, and plasma sGPVI were within normal ranges. WM platelets had reduced reticulation (P = .0012) whereas serum TPO levels were increased (P = .0040). WM plasma displayed slower thrombin generation (P = .0080) and WM platelets contributed less to endogenous thrombin potential (ETP; P = .0312). HD plasma or platelets incubated with IgM (50-60 mg/mL) displayed reduced spreading (P = .0002), aggregation (P < .0001), and ETP (P = .0081). Thus, alterations to thrombin potential and WB coagulation were detected in WM samples. WM IgM significantly impaired hemostasis in vitro. Platelet and coagulation properties are disturbed in patients with well-managed WM.


  • Open Access

    An Optimized Method of Collecting Murine Peripheral Blood and Dilution Correction for Accurate Blood Cell Enumeration

    by Vijay Bhoopalan, Elizabeth E. Gardiner, Amandeep Kaur

    Accurate measurement of whole blood counts from mice is an essential quantitative tool across the fields of vascular cell biology. In particular, the measurement of platelet counts can be challenging as the process relies upon good phlebotomy technique, the inclusion of a sufficient amount of the appropriate anticoagulant, and very often dilution of the sample to meet the sample volume requirements of an automated analyzer. To minimize sample dilution, blood collection tubes pre‐coated with the anticoagulant can be used; however, these are expensive and prone to blood clotting issues. Here, we describe a simple dilution correction method that accurately calculates blood‐to‐anticoagulant dilutions to generate appropriate volumes for automated blood cell analysis while minimizing blood clotting. We also discuss some simple steps that can be incorporated into blood collection methods to avoid artefacts during blood collection. Blood count data analysis involving volume correction and clot exclusion can significantly reduce variable blood cell count values among healthy untreated littermates. It also detects subtle changes in blood cell counts, mainly of platelets and RBCs in experimental settings, which can be masked in the absence of careful and precise volume correction. Blood count analysis with volume correction precisely determines mouse whole blood cell counts for investigators. The decreased variability in cell count values reduces the number of experimental animals required for meaningful analysis. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC.Basic Protocol: An optimized method of collecting murine peripheral blood and dilution correction for accurate blood cell enumerationThis article was corrected on 19 February 2024. See the end of the full text for details.